Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Pancreas ; 41(3): 374-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22228104

ABSTRACT

OBJECTIVES: This study aimed to investigate G17DT, an immunogen producing neutralizing antibodies against the tumor growth factors amidated and glycine-extended forms of gastrin-17, in the treatment of pancreatic cancer. METHODS: A randomized, double-blind, placebo-controlled, group-sequential multicenter trial of G17DT in patients with advanced pancreatic cancer unsuitable for or unwilling to take chemotherapy. Inclusion criteria were a Karnofsky performance score of 60 or higher and a life expectancy of more than 2 months. Patients received G17DT or placebo emulsion at weeks 0, 1, 3, 24, and 52. The primary end point was survival, and secondary end points were tolerability, Karnofsky performance. RESULTS: A total of 154 patients were recruited: 79 G17DT and 75 placebo. A final analysis of the intention-to-treat population, using a proportional hazards model, stratifying by disease stage and adjusting for interim analysis, gave a hazard ratio for mortality of 0.75 (95% confidence interval, 0.51-1.10, P = 0.138; G17DT/placebo). A conventional analysis without adjustment for disease stage or interim analysis, censoring for chemotherapy and excluding protocol violators, gave median survival periods of 151 (G17DT) and 82 days (placebo) (log-rank test, P = 0.03).Patients developing anti-G17DT responses (73.8%) survived longer than nonresponders or those on placebo (median survival, 176 vs 63 vs 83; log-rank test, P = 0.003). G17DT was well tolerated.


Subject(s)
Cancer Vaccines/therapeutic use , Gastrins/immunology , Gastrins/therapeutic use , Pancreatic Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Cancer Vaccines/adverse effects , Double-Blind Method , Europe , Female , Gastrins/adverse effects , Humans , Kaplan-Meier Estimate , Karnofsky Performance Status , Life Expectancy , Male , Middle Aged , Pancreatic Neoplasms/immunology , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Placebos , Proportional Hazards Models , Prospective Studies , Time Factors , Treatment Outcome
2.
Melanoma Res ; 14(6): 449-52, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15577314

ABSTRACT

Activating mutations in exon 15 of BRAF have been detected in a high proportion of cutaneous melanomas. To determine whether such mutations are a feature of conjunctival or uveal melanomas, we screened DNA from these tumours. Twenty-one conjunctival and 88 uveal tumours were included in the study. Mutation analysis of BRAF exons 11 and 15 was undertaken using a combination of conformationally sensitive gel electrophoresis and direct sequencing. Mutations in exon 15 were detected in three of the conjunctival tumours (two V599E and one E585 K). None of the uveal tumours possessed a BRAF mutation in either exon 15 or 11. We conclude that uveal melanomas arise independently of oncogenic BRAF mutations, but the development of a proportion of conjunctival tumours involves mutation of this gene.


Subject(s)
Conjunctival Neoplasms/genetics , Melanoma/genetics , Mutation/genetics , Proto-Oncogene Proteins B-raf/genetics , Uveal Neoplasms/genetics , Adult , Aged , Aged, 80 and over , DNA Mutational Analysis , DNA, Neoplasm/analysis , DNA, Neoplasm/isolation & purification , Epithelioid Cells/metabolism , Epithelioid Cells/pathology , Female , Humans , Male , Middle Aged , Nevus, Spindle Cell/metabolism , Nevus, Spindle Cell/pathology , Skin Neoplasms/genetics , Tumor Cells, Cultured
3.
Invest Ophthalmol Vis Sci ; 44(2): 458-62, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12556369

ABSTRACT

PURPOSE: Reports suggest that a subset of uveal melanoma is familial. The association of uveal melanoma with breast and ovarian cancer and the increased risk in BRCA2-linked families implicates germline BRCA2 mutations as the cause of a subset of uveal melanomas. Similarly, the association between cutaneous and uveal melanomas in some families, coupled with the high frequency of somatic deletions of the INK4A-ARF locus in uveal melanomas, strongly suggests that mutations in P16(INK4A) and P15 account for a proportion of uveal melanomas. METHODS: To examine this proposition, a systematically ascertained series of 385 patients with uveal melanoma were screened for germline mutations in BRCA2, P16(INK4A), P14(ARF), and P15. RESULTS: One patient was found to harbor a Gly35Ala substitution in exon 1alpha of P16(INK4A), which has previously been reported to be pathogenic. No mutations were detected in P14(ARF) or P15. None of the patients harbored germline nucleotide changes that lead to truncation or that create or disrupt consensus splice sites of BRCA2 or missense variants with clear pathogenic potential. CONCLUSIONS: These findings suggest that less than 2% of cases of uveal melanoma can be ascribed to germline mutations in BRCA2, P16(INK4A), P14(ARF), or P15. It is likely that mutations in other genes contribute to an inherited predisposition to uveal melanoma.


Subject(s)
BRCA2 Protein/genetics , Cell Cycle Proteins , Cyclin-Dependent Kinase Inhibitor p16/genetics , Germ-Line Mutation , Melanoma/genetics , Transcription Factors/genetics , Tumor Suppressor Protein p14ARF/genetics , Tumor Suppressor Proteins , Uveal Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Cyclin-Dependent Kinase Inhibitor p15 , DNA Mutational Analysis , DNA, Neoplasm/genetics , Female , Humans , Incidence , Male , Middle Aged , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL